Valuation: Black Diamond Therapeutics, Inc.

Market Cap 105M 92.47M 87.44M 79.31M 149M 10.09B 150M 1.05B 404M 5.15B 395M 386M 16.55B P/E 2026 *
-2.97x
P/E 2027 * -1.92x
Enterprise Value 105M 92.47M 87.44M 79.31M 149M 10.09B 150M 1.05B 404M 5.15B 395M 386M 16.55B EV / Sales 2026 *
16.8x
EV / Sales 2027 * -
Free-Float
99.34%
Yield 2026 *
-
Yield 2027 * -
1 day+0.82%
1 week-7.32%
Current month-12.62%
1 month-12.62%
3 months+4.86%
6 months-9.61%
Current year-24.49%
1 week 1.81
Extreme 1.81
1.97
1 month 1.81
Extreme 1.81
2.22
Current year 1.6
Extreme 1.6
3.97
1 year 1.6
Extreme 1.6
4.94
3 years 1.2
Extreme 1.195
7.66
5 years 1.18
Extreme 1.18
9.07
10 years 1.18
Extreme 1.18
46.25
Manager TitleAgeSince
Chief Executive Officer 62 15/09/2023
Chief Tech/Sci/R&D Officer 51 10/08/2021
Director of Finance/CFO 41 06/10/2024
Director TitleAgeSince
Director/Board Member 61 28/02/2017
Director/Board Member 47 30/11/2019
Director/Board Member 49 30/11/2018
Date Insider Type Main position Quantity % Market Cap. Importance
18/09/26 Free

Director

7,707 0.0134%
18/09/26 Free

Director

6,801 0.0118%
18/09/26
NEA Management Co. LLC
OtherCompany 0 0% -
Change 5-day change 1-year change 3-year change Capi.($)
+1.37%-7.32%-50.80%-36.06% 105M
-0.37%-3.67%+57.21%+87.75% 71.81B
+0.52%-0.75%+38.91%+84.32% 60.06B
+0.19%+1.61%+35.10%+17.20% 27.93B
-2.29%-4.60%-18.63%+356.50% 25.7B
-1.29%-2.50%+0.25%-9.47% 24.89B
+0.28%+1.89%+26.75%-7.42% 20.92B
-1.70%+0.43%+150.24%+323.16% 15.04B
-1.26%-0.79%+42.20%+164.03% 14.46B
+3.91%-3.51%-4.56%+517.49% 13.87B
Average -0.09%-1.98%+27.67%+149.75% 27.48B
Weighted average by Cap. -0.21%-1.91%+37.54%+127.45%

Financials

2026 *2027 *
Net sales 6.25M 5.5M 5.2M 4.71M 8.85M 600M 8.91M 62.24M 24.04M 306M 23.46M 22.96M 984M -
Net income -36.96M -32.51M -30.74M -27.88M -52.36M -3.55B -52.67M -368M -142M -1.81B -139M -136M -5.82B -64.65M -56.86M -53.77M -48.77M -91.59M -6.21B -92.12M -644M -249M -3.17B -243M -237M -10.18B
Net Debt - -
Logo Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
Employees
21
Date Price Change Volume
29/09/26 US$1.835 +0.27% 61,306
28/09/26 US$1.830 -2.66% 648,334
25/09/26 US$1.880 -0.53% 378,802
24/09/26 US$1.890 -0.53% 460,230
23/09/26 US$1.900 -4.04% 613,848
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
1.830USD
Average target price
10.00USD
Spread / Average Target
+446.45%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BDTX Stock